IGC Pharma, Inc. (FRA:IGS1)

IGC Pharma Statistics

Total Valuation

IGC Pharma has a market cap or net worth of EUR 25.56 million. The enterprise value is 24.71 million.

Market Cap	25.56M
Enterprise Value	24.71M

Important Dates

The last earnings date was Monday, November 17, 2025.

Earnings Date	Nov 17, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	92.87M
Shares Outstanding	n/a
Shares Change (YoY)	+19.49%
Shares Change (QoQ)	+8.95%
Owned by Insiders (%)	8.11%
Owned by Institutions (%)	20.74%
Float	85.33M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	27.11
PB Ratio	3.71
P/TBV Ratio	9.33
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-4.50
EV / Sales	25.90
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-5.15

Financial Position

The company has a current ratio of 1.32, with a Debt / Equity ratio of 0.02.

Current Ratio	1.32
Quick Ratio	0.79
Debt / Equity	0.02
Debt / EBITDA	n/a
Debt / FCF	-0.03
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -83.34% and return on invested capital (ROIC) is -63.56%.

Return on Equity (ROE)	-83.34%
Return on Assets (ROA)	-50.31%
Return on Invested Capital (ROIC)	-63.56%
Return on Capital Employed (ROCE)	-98.37%
Revenue Per Employee	13,466
Profits Per Employee	-78,485
Employee Count	70
Asset Turnover	0.11
Inventory Turnover	0.55

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -21.26% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-21.26%
50-Day Moving Average	0.32
200-Day Moving Average	0.29
Relative Strength Index (RSI)	32.79
Average Volume (20 Days)	468

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	0.33

Income Statement

In the last 12 months, IGC Pharma had revenue of EUR 942,644 and -5.49 million in losses. Loss per share was -0.07.

Revenue	942,644
Gross Profit	435,525
Operating Income	-6.90M
Pretax Income	-5.49M
Net Income	-5.49M
EBITDA	-6.41M
EBIT	-6.90M
Loss Per Share	-0.07

Balance Sheet

The company has 963,099 in cash and 124,436 in debt, giving a net cash position of 838,663.

Cash & Cash Equivalents	963,099
Total Debt	124,436
Net Cash	838,663
Net Cash Per Share	n/a
Equity (Book Value)	6.90M
Book Value Per Share	0.07
Working Capital	417,627

Cash Flow

In the last 12 months, operating cash flow was -4.73 million and capital expenditures -69,889, giving a free cash flow of -4.80 million.

Operating Cash Flow	-4.73M
Capital Expenditures	-69,889
Free Cash Flow	-4.80M
FCF Per Share	n/a

Margins

Gross Margin	46.20%
Operating Margin	-731.92%
Pretax Margin	-582.82%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

IGC Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-19.49%
Shareholder Yield	-19.49%
Earnings Yield	-21.50%
FCF Yield	-18.76%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on April 19, 2013. It was a reverse split with a ratio of 0.1.

Last Split Date	Apr 19, 2013
Split Type	Reverse
Split Ratio	0.1

Scores

IGC Pharma has an Altman Z-Score of -10.12 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-10.12
Piotroski F-Score	3